Steve Brannan

Company: Karuna Therapeutics

Job title: Former Chief Medical Officer

Seminars:

Panel Discussion: Assessing the Pros & Cons of Muscarinic PAMs vs. Agonists for Side Effect Alleviation & Efficacy Across Symptom Domains 4:30 pm

What are the main advantages and disadvantages of preclinically developing and clinically investigating a muscarinic receptor agonist compared to a PAM, and how are the disadvantages currently being addressed? Evaluating differences in efficacy signals: are there specific indications where one approach might be more beneficial than the other? What are the differences in side effect…Read more

day: Day One PM

Cobenfy Beyond Psychosis: What is the Potential of Muscarinics to Address the High Unmet Need for Cognitive & Negative Symptom Management? 5:00 pm

Exploring promising avenues for Cobenfy to target symptoms beyond psychosis Outlining future directions for Cobenfy to be investigated for negative schizophrenia symptoms and cognitive-related symptoms across psychiatry: how could it be used to achieve functional recovery? Addressing key obstacles to anticipate and address when targeting negative symptoms and cognitive deficits in clinical populationsRead more

day: Day One PM